A new trading day began on Tuesday, with Agios Pharmaceuticals Inc (NASDAQ: AGIO) stock price up 7.26% from the previous day of trading ,before settling in for the closing price of $27.70. AGIO’s price has ranged from $19.80 to $35.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 2.66%. Meanwhile, its annual earnings per share averaged -5.34%. With a float of $54.74 million, this company’s outstanding shares have now reached $55.95 million.
Let’s determine the extent of company efficiency that accounts for 383 employees.
Agios Pharmaceuticals Inc (AGIO) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Agios Pharmaceuticals Inc is 2.58%, while institutional ownership is 106.21%. The most recent insider transaction that took place on Mar 07 ’24, was worth 40,632. In this transaction Director of this company sold 1,285 shares at a rate of $31.62, taking the stock ownership to the 5,524 shares. Before that another transaction happened on Mar 06 ’24, when Company’s Director sold 4,415 for $31.99, making the entire transaction worth $141,236. This insider now owns 6,809 shares in total.
Agios Pharmaceuticals Inc (AGIO) Recent Fiscal highlights
In its latest quarterly report, released on 12/30/2023, the company reported earnings of -$1.72 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.66 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.00% during the next five years compared to -0.98% drop over the previous five years of trading.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
Here are Agios Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 11.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 62.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.33, a number that is poised to hit -1.64 in the next quarter and is forecasted to reach -5.89 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Looking closely at Agios Pharmaceuticals Inc (NASDAQ: AGIO), its last 5-days average volume was 0.64 million, which is a drop from its year-to-date volume of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 38.79%. Additionally, its Average True Range was 1.16.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 60.18%, which indicates a significant increase from 59.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.00% in the past 14 days, which was lower than the 45.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.47, while its 200-day Moving Average is $25.39. However, in the short run, Agios Pharmaceuticals Inc’s stock first resistance to watch stands at $30.44. Second resistance stands at $31.17. The third major resistance level sits at $32.48. If the price goes on to break the first support level at $28.40, it is likely to go to the next support level at $27.08. Now, if the price goes above the second support level, the third support stands at $26.35.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
With a market capitalization of 1.67 billion, the company has a total of 56,195K Shares Outstanding. Currently, annual sales are 26,820 K while annual income is -352,090 K. The company’s previous quarter sales were 7,100 K while its latest quarter income was -95,940 K.
